

1 Reaction of 1-substituted 3-(2-hydroxyethylamino)quinoline- 2,4(1*H*,3*H*)-diones with isothiocyanic acid

3 Antonín Klásek^{1*}, Antonín Lyčka², Michal Rouchal¹, Radek Bartošík¹

¹ Department of Chemistry, Faculty of Technology, Tomas Bata University,


⁵ CZ-76272 Zlín, Czech Republic; e-mail: klasek@utb.cz

⁶ ² Research Institute for Organic Syntheses (VUOS),

⁷ CZ-533 54 Pardubice, Czech Republic; e-mail: Antonin.Lycka@vuos.com

Submitted November 7, 2019

Accepted after revision January 30, 2020



8 3-Chloroquinoline-2,4-diones react with ethanolamine in the form of 3-(3-hydroxyethylamino)quinoline-2,4-diones. These compounds
9 afford, depending on substituents in positions 1 and 3, four different products from their reaction with isothiocyanic acid: 3-(2-hydroxy-
10 ethyl)-2-thioxo-3,3a-dihydro-1*H*-imidazo[4,5-*c*]quinolin-4(5*H*)-ones, 9*b*-hydroxy-3-(2-hydroxyethyl)-2-thioxo-3,3*a*,5,9*b*-tetrahydro-1*H*-
11 imidazo[4,5-*c*]quinolin-4(2*H*)-ones, 3-(2-hydroxyethyl)-2-thioxo-2,3-dihydro-1*H*-imidazo[4,5-*c*]quinolin-4(5*H*)-ones, or 1'-methyl-7*a*-phenyl-
12 5-thioxo-3,5,6,7*a*-tetrahydro-2*H*-spiro[imidazo[5,1-*b*]oxazole-7,3'-indolin]-2'-one.

13 **Keywords:** isocyanic acid, isothiocyanic acid, 2-thioxo-1*H*-imidazo[4,5-*c*]quinolin-4(2*H*)-ones, 2-thioxo-1*H*-imidazo[4,5-*c*]quinolin-4
14 (5*H*)-ones, quinoline-2,4-diones, nuclear magnetic resonance, rearrangement.


15 The chemistry of quinolinediones, and in particular,
16 3-aminoquinoline-2,4-diones have been of interest to our
17 group for a long time.¹ In the literature, two derivatives of
18 3-aminoquinoline-2,4-diones are mentioned in connection
19 with their biological activity. 3-Amino-3-(4-fluorophenyl)-
20 1*H*-quinoline-2,4-dione is effective against oxidative stress-
21 related diseases² and inhibits cisplatin-induced hearing
22 loss through suppression of reactive oxygen species.^{3,4}
23 A similar effect is exhibited by 3-amino-6-fluoro-3-
24 (4-fluorophenyl)-1*H*-quinoline-2,4-dione.⁴ Therefore, we
25 tried to prepare some 3-aminoquinoline-2,4-dione deriva-
26 tives with the 3-amino group fixed in a fused ring structure.
27 3-Aminoquinoline-2,4(1*H*,3*H*)-diones were prepared in our
28 laboratory from 3-chloroquinoline-2,4-diones and ammonia
29 or primary amines.^{1*a*} We found, that these compounds
30 undergo molecular rearrangements when reacting with
31 isocyanic acid that is formed from urea in boiling acetic
32 acid. Through this synthetic route, 2,6-dihydroimidazo[1,5-*c*]-
33 quinolone-2,4-diones and rearranged 3,3*a*-dihydro-5*H*-
34 imidazo[4,5-*c*]quinazoline-3,5-diones, 3-(3-acylureido)-2,3-
35 dihydro-1*H*-indol-2-ones, and 4-alkylidene-1'*H*-spiro-
36 [imidazolidine-5,3'-indole]-2,2'-diones were prepared.^{1*b,c*}

Later we found that the preferable source of isocyanic acid³⁷
is sodium cyanate and that an acceptable source of³⁸
isothiocyanic acid is potassium thiocyanate, both in acetic³⁹
acid solution. Under these conditions, we prepared new⁴⁰
heterocycles, e. g., spiro-linked imidazolidine-2-thiones and⁴¹
thioxo derivatives of imidazo[1,5-*c*]quinazolin-5-ones and⁴²
imidazo[4,5-*c*]quinolin-4-ones.^{1*g*} ⁴³

In an effort to discover an influence of other substituents⁴⁴
in the molecule of the amine, we chose ethanolamine as an⁴⁵
easily accessible and inexpensive reagent. In our last⁴⁶
paper,^{1*h*} we described its reaction with 3-chloroquinoline-⁴⁷
2,4-diones **1**. According to expectations, 3-(2-hydroxy-⁴⁸
ethylamino)quinoline-2,4-diones **2** were obtained and their⁴⁹
reaction with isocyanic acid afforded mainly 5-hydroxy-1-⁵⁰
(2-hydroxyethyl)-1*H*-spiro[imidazolidine-4,3'-indole]-2,2'-⁵¹
diones **3**, but also 3-(2-hydroxyethyl)-3,3*a*-dihydro-2*H*-⁵²
imidazo[4,5-*c*]quinoline-2,4-(5*H*)-diones **4** (Scheme 1). ⁵³

In this paper, the analogous reaction of compounds **2**⁵⁴
with isothiocyanic acid is described. The starting com-⁵⁵
pounds **2a–f** were reacted with isothiocyanic acid⁵⁶
generated *in situ* from potassium thiocyanate in acetic acid.⁵⁷
The composition of products from this reaction was⁵⁸

Scheme 1



a $\text{R}^1 = \text{Me}$, $\text{R}^2 = \text{Bu}$; b $\text{R}^1 = \text{Me}$, $\text{R}^2 = \text{Bn}$; c $\text{R}^1 = \text{Me}$, $\text{R}^2 = \text{Ph}$; d $\text{R}^1 = \text{Ph}$, $\text{R}^2 = \text{Bu}$; e $\text{R}^1 = \text{Ph}$, $\text{R}^2 = \text{Bn}$; f $\text{R}^1 = \text{R}^2 = \text{Ph}$

1 different from that with isocyanic acid and comprised three
2 different *N*-hydroxyethyl substituted 2-thioxo-1*H*-imidazo-
3 [4,5-*c*]quinolin-4-ones **5a,c,d,f**, **6a,b,d,e,f**, and **7b,e**, and, in
4 one case, a product of molecular rearrangement **8c** with
5 spiro[imidazo[5,1-*b*]oxazole-7,3'-indolin]-2'-one structure
6 (Scheme 1, Table 1). It is noteworthy that the respective
7 non-cyclized thioureas derived of compounds **2** were never
8 isolated.

9 It can be expected, that compounds **3** and **5** can probably
10 arise from hydroxyethyl derivative **2** by known Marckwald
11 synthesis.⁵ However, no strong acid is present in the
12 reaction mixture. Therefore, we offer another inter-
13 pretation, based on the formation of isocyanic or isothio-
14 cyanic acids during the reaction. With moderately strong
15 isocyanic acid ($\text{p}K_{\text{a}} 3.7$),⁶ arising from the isomerization of
16 weak cyanic acid ($\text{p}K_{\text{a}} 5.4$),⁷ compounds **2a,b,d-f** react to
17 form^{1h} compounds **3a,b** and **4d-f**. However, isothiocyanic
18 acid is a very strong acid ($\text{p}K_{\text{a}} -1.3$)^{7,8} and arises from the
19 isomerization of weak thiocyanic acid ($\text{p}K_{\text{a}} 5.4$).⁷ Its
20 reaction with 3-aminoquinoline-2,4(1*H*,3*H*)-diones **2** afforded
21 not only compounds **5a,c,d,f** which are thio analogs of
22 products **4**, obtained by the reaction with isocyanic acid,
23 but also new structures **7b,e**, due to the influence of strong
24 dealkylated products **7b,e**, due to the influence of strong
25 isothiocyanic acid.

26 The explanation of the origin of the obtained compounds
27 was based on the NMR spectroscopy. Yellow or orange
28 compounds **5a,c,d,f** were produced in moderate yield from
29 compounds **2a,c,d,f** through the reaction with HNCS. The
30 signals of NCH_2 protons resonate more downfield than the
31 signals of OCH_2 protons. It was surprising, however, the
32 location was proved by 2D NMR (mainly HSQC and
33 HSQC–TOCSY). Protons are situated on the periphery of a
34 molecule and their resonance can be relatively easily
35 influenced by different neighbouring groups.

36 When compound **5a** was kept for one month in $\text{DMSO-}d_6$,
37 the NMR spectrum indicated conversion into compound
38 **6a**, the product of a nucleophilic attack on compound **5a** by
39 H_2O , with a yield of about 65%. Typical ^{13}C chemical
40 shifts in the spectra of this condensation product agree with
41 those in oxa-analog of compound **6a**, except that it has a


Table 1. Products of the reactions of compounds **2a-f** with HNCS

Starting material	R^1	R^2	Product (yield, %)
2a	Me	Bu	5a (24), 6a (16), 2a* (26), <i>N</i> -methylisatin (7)
2b	Me	Bn	6b (8), 7b (8)
2c	Me	Ph	5c (11), 8c (49)
2d	Ph	Bu	5d (30), 6d (9), 2d* (33), <i>N</i> -phenylisatin (3)
2e	Ph	Bn	6e (27), 7e (8)
2f	Ph	Ph	5f (31), 6f (23), <i>N</i> -phenylisatin (6)

* Recovered starting material.


different alkyl substituent at N-3 atom.¹¹ On the other hand,⁴²
compounds **6** can also be an antecedent of compounds **5**.^{1g,43}
Indeed, yellow compounds **5a,f** were prepared in high
yields through the dehydration of colorless **6a,f** upon
treatment with P_2O_5 (Scheme 2). However, the same treat-
ment of compound **6e** does not result in compound **5e**,
instead, colorless compound **9e** was isolated with 39%
yield (Scheme 2). It is likely that this new compound must
originate from *C*-debenzylation and subsequent *S*-benzylation
with benzyl cation. 51

Scheme 2



In the first-order positive-ion ESI-MS spectra of **52**
compounds **5a,c,d,f**, we observed three singly charged
signals, which we assigned to $[\text{M}+\text{H}]^+$, $[\text{M}+\text{Na}]^+$, and
 $[\text{M}+\text{K}]^+$. In the first-order negative-ion ESI-MS spectra of
compounds **6**, singly charged signals assigned to $[\text{M}-\text{H}]^-$,
 $[\text{M}+\text{Cl}]^-$, and $[2\text{M}-\text{H}]^-$ were detected. Moreover, singly
charged ion with $m/z 150$ in the mass spectra of compounds
6a,b and $m/z 212$ in the mass spectra of compounds
6d,e,f were observed in the negative ionization mode. We **60**

Scheme 3



1 assigned these ions to 1-[2-(methylamino)phenyl]ethanolate
 2 and 1-[2-(phenylamino)phenyl]ethanolate, respectively.
 3 We propose that these ions are products of in-source
 4 fragmentation of deprotonated molecular ion $[M-H]^-$.

5 The only product of molecular rearrangement is
 6 compound **8c**, having two aliphatic quaternary carbons,
 7 unlike its isomer **5c**. In agreement with our preceding
 8 results, this compound must originate from the molecular
 9 rearrangement of compound **6c** (Scheme 3). In three cases
 10 (Table 1), the corresponding isatins were isolated in
 11 addition to the main product, which is indicative of the
 12 extensive degradation of the starting compound **2** by
 13 isothiocyanic acid. Compounds **7b,e** (Scheme 3) arise from
 14 the debenzoylation of starting compounds **2b,e**, bearing a
 15 benzyl group at position 3. Such reaction, resulting from
 16 the presence of strongly acidic isothiocyanic acid, has been
 17 observed before.^{1a}

18 In conclusion, we would like to emphasize that our
 19 results provide new information about the behavior of
 20 reactive quinoline-2,4-dione systems. 3-(2-Hydroxyethyl-
 21 amino)quinolinediones, prepared from 3-chloroquinoline-
 22 dione and ethanolamine, react with isothiocyanic acid to
 23 form four different heterocyclic structures: three related
 24 imidazo[4,5-*c*]quinolin-4-ones and spiro[imidazo[5,1-*b*]-
 25 oxazole-7,3'-indolin]-2'-one, a new tetracyclic spiro system
 26 that has not been previously described. Unfortunately, the
 27 latter compound arises in only one case and our
 28 experiments on the preparation of other similar spiro
 29 compounds were so far unsuccessful. This study also
 30 demonstrated a new example of benzyl group migration
 31 from carbon to sulfur atom. An important result is also
 32 dehydration of 9b-hydroxy-2-thioxo-4*H*-imidazo[4,5-*c*]-
 33 quinolin-4-ones to 2-thioxo-4*H*-imidazo[4,5-*c*]quinolin-
 34 4-ones enabling preparation of these compounds as the
 35 only product by the two-step reaction from starting
 36 3-aminoquinoline-2,4-diones. The prepared compounds are
 37 suitable for biological testing as well as further synthetic
 38 elaboration.

Experimental

39 IR spectra were recorded on a Smart OMNI-
 40 Transmission Nicolet iS10 spectrophotometer in KBr
 41 pellets. ¹H, ¹³C, and ¹⁵N NMR spectra were recorded on a
 42 Bruker Avance III HD 500 spectrometer (500, 125, and

50 MHz, respectively) in DMSO-*d*₆; the ¹H and ¹³C
 44 chemical shifts are given with respect to internal standard
 45 TMS; for ¹⁵N spectra, MeNO₂ was used as an external
 46 standard in a co-axial capillary; signal assignments were
 47 carried out using APT and 2D experiments (gradient-selected
 48 (gs) ¹H-¹H COSY, gs-¹H-¹H TOCSY, gs-¹H-¹³C HMQC,
 49 gs-¹H-¹³C HMQC-RELAY, gs-¹H-¹³C HMBC, gs-¹H-¹⁵N
 50 HMBC).^{9–11} Mass spectra were recorded on a Bruker
 51 Daltonics amaZon X ion-trap mass spectrometer, equipped
 52 with an ESI source; individual samples were injected into
 53 the ESI source as MeOH-H₂O solutions (concentration
 54 500 ng/ml) via a syringe pump with a constant flow rate of
 55 3 ml/min; *m/z* range 50–1500, electrospray voltage
 56 ±4.2 kV, drying gas temperature 220°C, drying gas flow
 57 rate 6.0 dm³/min, nebulizer pressure 55.16 kPa, capillary
 58 exit voltage 140 V; N₂ was used as both nebulizing and
 59 drying gas. Elemental analysis was carried out on a Thermo
 60 Fisher Scientific Flash EA 1112 elemental analyzer. Melting
 61 points were determined using a Kofler block. TLC was
 62 performed using Macherey-Nagel Alugram® SIL G/UV₂₅₄
 63 foil plates; elution with PhH-AcOEt, 4:1, CHCl₃-EtOH,
 64 9:1, or CHCl₃-AcOEt, 7:3. Column chromatography was
 65 carried out on Merck silica gel (grade 60, 70–230 mesh);
 66 elution with CHCl₃, then CHCl₃-EtOH, 99:1→8:2, or PhH,
 67 then PhH-AcOEt, 99:1→8:2.

68
 69 Compounds **2a–f** were prepared from the respective
 70 compounds **1a–f** and ethanolamine.^{1a}

71 **Reaction of compounds 2a–f with HNCS** (General
 72 method). KSCN (0.874 g, 9 mmol) was added to a solution
 73 of compound **2a–f** (1.5 mmol) in AcOH (4.5 ml), and the
 74 mixture was stirred for 3 h at 50°C. The course of the
 75 reaction was monitored by TLC. After cooling, the mixture
 76 was poured onto crushed ice (20 ml) and extracted with
 77 CHCl₃ (5 × 15 ml) and then with AcOEt (5 × 15 ml). The
 78 combined extracts were dried with anhydrous Na₂SO₄ and
 79 evaporated to dryness. The residue was separated by
 80 column chromatography.

81 **3a-Butyl-3-(2-hydroxyethyl)-5-methyl-2-thioxo-2,3,3a,5-81**
tetrahydro-4*H*-imidazo[4,5-*c*]quinolin-4-one (5a) was
 82 prepared from compound **2a**. Yield 24%. Orange solid. Mp
 83 135–137°C (PhH-cyclohexane). IR spectrum, ν, cm⁻¹:
 84 3376, 2961, 2932, 2875, 1690, 1661, 1609, 1589, 1471,
 85 1439, 1389, 1334, 1287, 1255, 1230, 1211, 1178, 1160,
 86 1110, 1072, 1050, 990, 967, 775, 758, 730, 699, 683, 671, 87

1 608, 520. ¹H NMR spectrum, δ , ppm (*J*, Hz): 0.68 (3H, t, *J* = 7.3, 4-CH₃ Bu); 0.66–0.76 (2H, m, 2-CH₂ Bu); 1.02–1.13 (2H, m, 3-CH₂ Bu); 1.81–1.90 (1H, m) and 2.33–2.41 (1H, m, 1-CH₂ Bu); 3.32 (3H, s, 5-CH₃); 3.78–3.88 (3H, m, CH₂O, NCH₂); 4.03–4.10 (1H, m, NCH₂); 4.90 (1H, br. s, OH); 7.32–7.37 (1H, m, H-7); 7.43–7.47 (1H, m, H-9); 7.74–7.79 (1H, m, H-8); 7.90–7.94 (1H, m, H-6). ¹³C NMR spectrum, δ , ppm: 13.6 (C-4 Bu); 21.1 (C-3 Bu); 24.2 (C-2 Bu); 29.9 (5-CH₃); 36.5 (C-1 Bu); 47.2 (NCH₂); 56.8 (CH₂O); 81.2 (C-3a); 116.0 (C-5a); 116.8 (C-9); 124.1 (C-7); 125.8 (C-6); 135.7 (C-8); 141.7 (C-9a); 166.6 (C-4); 183.8 (C-9b); 194.5 (C-2). Mass spectrum, *m/z* (*I*_{rel.}, %): 685 [2M+Na]⁺ (5), 370 [M+K]⁺ (10), 354 [M+Na]⁺ (100), 351 [2M+Ca]²⁺ (9), 332 [M+H]⁺ (12). Found, %: C 61.45; H 6.60; N 12.79; S 9.64. C₁₇H₂₁N₃O₂S. Calculated, %: C 61.61; H 6.39; N 12.68; S 9.67.

3-(2-Hydroxyethyl)-5-methyl-3a-phenyl-2-thioxo-2,3,3a,5-tetrahydro-4H-imidazo[4,5-c]quinolin-4-one (5c) was prepared from compound **2c**. Yield 11%. Yellow solid. Mp 170–177°C (PhH–hexane). IR spectrum, ν , cm⁻¹: 3556, 3056, 2937, 2897, 1678, 1608, 1588, 1491, 1468, 1447, 1400, 1361, 1326, 1284, 1222, 1168, 1143, 1123, 1050, 1001, 968, 952, 934, 809, 760, 724, 695, 664, 610, 571, 529. ¹H NMR spectrum, δ , ppm (*J*, Hz): 3.17–3.29 (1H, m) and 3.62–3.74 (1H, m, CH₂O); 3.44 (3H, s, 5-CH₃); 3.47–26.3.59 (1H, m) and 3.68–3.80 (1H, m, NCH₂); 4.73 (1H, t, *J* = 5.7, OH); 6.98–7.02 (2H, m, H-2,6 Ph); 7.23–7.28 (1H, m, H-7); 7.36–7.43 (4H, m, H-9, H-3,4,5 Ph); 7.62–7.66 (1H, m, H-8); 7.82–7.92 (1H, m, H-6). ¹³C NMR spectrum, δ , ppm: 30.4 (5-CH₃); 47.4 (NCH₂); 56.2 (CH₂O); 83.4 (C-3a); 116.7 (C-5a); 116.8 (C-9); 124.1 (C-7); 125.9 (C-2,6 Ph); 126.1 (C-6); 130.1 (C-3,5 Ph); 130.4 (C-4 Ph); 131.6 (C-1 Ph); 135.5 (C-8); 141.2 (C-9a); 165.0 (C-4); 183.1 (C-9b); 195.0 (C-2). Mass spectrum, *m/z* (*I*_{rel.}, %): 725 [2M+Na]⁺ (9), 390 [M+K]⁺ (7), 374 [M+Na]⁺ (100), 371 [2M+Ca]²⁺ (8), 352 [M+H]⁺ (17). Found, %: C 64.86; H 4.91; N 11.77; S 9.00. C₁₉H₁₇N₃O₂S. Calculated, %: C 64.94; H 4.88; N 11.96; S 9.12.

3a-Butyl-3-(2-hydroxyethyl)-5-phenyl-2-thioxo-2,3,3a,5-tetrahydro-4H-imidazo[4,5-c]quinolin-4-one (5d) was prepared from compound **2d**. Yield 30%. Yellow solid. Mp 161–166°C (PhH–hexane). IR spectrum, ν , cm⁻¹: 3454, 3066, 2962, 2929, 2871, 1689, 1608, 1590, 1490, 1467, 1432, 1385, 1340, 1322, 1281, 1245, 1225, 1164, 1108, 1066, 1033, 1004, 962, 859, 777, 754, 733, 696, 633, 610, 582, 516. ¹H NMR spectrum, δ , ppm (*J*, Hz): 0.78 (3H, t, *J* = 7.3, 4-CH₃ Bu); 0.75–0.85 (2H, m, 2-CH₂ Bu); 1.07–1.23 (2H, m, 3-CH₂ Bu); 2.15–2.27 (1H, m) and 2.48–2.55 (1H, m, 1-CH₂ Bu); 3.73–3.88 (3H, m, CH₂O, NCH₂); 4.05–4.11 (1H, m, NCH₂); 4.83 (1H, t, *J* = 5.3, OH); 6.39–6.44 (1H, m, H-9); 7.27–7.34 (3H, m, H-7, H-2,6 Ph); 7.47–7.64 (4H, m, H-8, H-3,4,5 Ph); 7.96–8.01 (1H, m, H-6). ¹³C NMR spectrum, δ , ppm: 13.6 (C-4 Bu); 21.1 (C-3 Bu); 24.4 (C-2 Bu); 36.4 (C-1 Bu); 47.2 (NCH₂); 56.8 (CH₂O); 81.5 (C-3a); 115.7 (C-9); 117.3 (C-5a); 124.1 (C-7); 125.9 (C-6); 129.4 (C-2,6 Ph); 129.9 (C-4 Ph); 130.3 (C-3,5 Ph); 130.4 (C-1 Ph); 136.8 (C-8); 142.8 (C-9a); 166.9 (C-4); 183.7 (C-9b); 194.9 (C-2). Mass spectrum, *m/z* (*I*_{rel.}, %): 809 [2M+Na]⁺ (5), 432 [M+K]⁺ (11), 416 [M+Na]⁺ (100), 413 [2M+Ca]²⁺ (11), 394 [M+H]⁺ (15). Found, %: C 67.05;

H 6.10; N 10.65; S 8.02. C₂₂H₂₃N₃O₂S. Calculated, %: C 67.15; H 5.89; N 10.68; S 8.15.

3-(2-Hydroxyethyl)-3a,5-diphenyl-2-thioxo-2,3,3a,5-tetrahydro-4H-imidazo[4,5-c]quinolin-4-one (5f) was prepared from compound **2f**. Yield 31%. Orange solid. Mp 178–180°C (PhH–cyclohexane). IR spectrum, ν , cm⁻¹: 3451, 3061, 2361, 1702, 1608, 1587, 1492, 1466, 1449, 1394, 1359, 1309, 1289, 1246, 1229, 1165, 1140, 1060, 1037, 1003, 953, 771, 733, 721, 703, 694, 671, 611, 594, 568, 516. ¹H NMR spectrum, δ , ppm (*J*, Hz): 3.10–3.19 (1H, m) and 3.59–3.66 (1H, m, CH₂O); 3.49–3.58 (1H, m) and 3.79–3.86 (1H, m, NCH₂); 4.68 (1H, t, *J* = 5.7, OH); 6.29–6.34 (1H, m, H-9); 7.17–7.26 (3H, m, H-7, H-2,6 3a-Ph); 7.39–7.69 (9H, m, H-8, H 5-Ph, H-3,4,5 3a-Ph); 7.97–8.02 (1H, m, H-6). ¹³C NMR spectrum, δ , ppm: 47.3 (NCH₂); 56.1 (CH₂O); 83.6 (C-3a); 116.6 (C-5a); 117.4 (C-9); 124.4 (C-7); 126.1 (C-2,6 3a-Ph); 126.3 (C-6); 128.9 (C-2,6 5-Ph); 130.1 (C-4 5-Ph); 130.3 (C-3,5 3a,5-Ph); 130.5 (C-4 3a-Ph); 131.5 (C-1 5-Ph); 135.1 (C-8); 136.8 (C-1 3a-Ph); 142.3 (C-9a); 165.2 (C-4); 182.9 (C-9b); 195.0 (C-2). Mass spectrum, *m/z* (*I*_{rel.}, %): 849 [2M+Na]⁺ (8), 452 [M+K]⁺ (8), 436 [M+Na]⁺ (100), 433 [2M+Ca]²⁺ (21), 414 [M+H]⁺ (16). Found, %: C 69.81; H 4.75; N 10.18; S 7.74. C₂₄H₁₉N₃O₂S. Calculated, %: C 69.71; H 4.63; N 10.16; S 7.75.

3a-Butyl-9b-hydroxy-3-(2-hydroxyethyl)-5-methyl-2-thioxo-1,2,3,3a,5,9b-hexahydro-4H-imidazo[4,5-c]quinolin-4-one (6a) was prepared from compound **2a**. Yield 16%. Colorless solid. Mp 203–217°C (AcOEt). IR spectrum, ν , cm⁻¹: 3418, 3226, 2958, 2933, 2871, 1662, 1605, 1478, 1436, 1365, 1303, 1255, 1205, 1170, 1122, 1054, 1005, 989, 956, 939, 910, 865, 843, 757, 721, 691, 623, 590, 518, 490. ¹H NMR spectrum, δ , ppm (*J*, Hz): 0.68 (3H, t, *J* = 7.3, 4-CH₃ Bu); 0.70–0.76 (1H, m) and 0.92–1.01 (1H, m, 2-CH₂ Bu); 1.07–1.15 (2H, m, 3-CH₂ Bu); 1.95 (2H, m, 1-CH₂ Bu); 3.29 (3H, s, 5-CH₃); 3.57–3.65 (2H, m, CH₂O); 3.83–3.90 (2H, m, NCH₂); 4.60 (1H, t, *J* = 6.4, OH); 6.87 (1H, s, 9b-OH); 7.12–7.20 (2H, m, H-6,8); 7.38–7.43 (1H, m, H-7); 7.72–7.79 (1H, m, H-9); 9.14 (1H, s, NH). ¹³C NMR spectrum, δ , ppm: 13.5 (C-4 Bu); 22.5 (C-3 Bu); 24.1 (C-2 Bu); 29.4 (5-CH₃); 31.3 (C-1 Bu); 46.4 (NCH₂); 59.0 (CH₂O); 72.3 (C-3a); 84.7 (C-9b); 114.5 (C-6); 123.3 (C-8); 123.7 (C-9a); 126.3 (C-9); 130.0 (C-7); 136.2 (C-5a); 168.6 (C-4); 181.3 (C-2). ¹⁵N NMR spectrum, δ , ppm (*J*, Hz): -237.9 (d, ¹*J* = 95.6, 1-NH); -252.6 (N-5); -253.3 (N-3). Mass spectrum, *m/z* (*I*_{rel.}, %): 721.2 [2M+Na]⁺ (5), 388 [M+K]⁺ (11), 372 [M+Na]⁺ (100), 369 [2M+Ca]²⁺ (26), 350 [M+H]⁺ (6). Mass spectrum, *m/z* (*I*_{rel.}, %): 697 [2M-H]⁻ (66), 384 [M+³⁵Cl]⁻ (23), 348 [M-H]⁻ (100), 150 (86). Found, %: C 58.36; H 6.74; N 11.86; S 8.98. C₁₇H₂₃N₃O₃S. Calculated, %: C 58.43; H 6.63; N 12.02; S 9.18.

3a-Benzyl-9b-hydroxy-3-(2-hydroxyethyl)-5-methyl-2-thioxo-1,2,3,3a,5,9b-hexahydro-4H-imidazo[4,5-c]quinolin-4-one (6b) was prepared from compound **2b**. Yield 8%. Colorless solid. Mp 205–215°C (PhH–cyclohexane). IR spectrum, ν , cm⁻¹: 3244, 2937, 2887, 1662, 1606, 1477, 1410, 1369, 1304, 1249, 1197, 1132, 1075, 1034, 1016, 961, 944, 896, 832, 790, 756, 740, 701, 621, 596, 550, 526, 456. ¹H NMR spectrum, δ , ppm (*J*, Hz): 3.18 (1H, d, *J* = 16.0) and 3.36 (1H, d, *J* = 16.0, CH₂Ph); 120

13.35 (3H, s, 5-CH₃); 3.65–3.81 (2H, s, CH₂O); 4.04–4.08 (2H, m, NCH₂); 4.65 (1H, t, *J* = 6.3, OH); 6.54–6.56 (1H, m, H-6); 6.81–6.93 (5H, m, H Ph); 6.97–7.02 (1H, m, H-8); 7.07–7.12 (1H, m, H-7); 7.15 (1H, s, 9b-OH); 7.64–7.67 (1H, m, H-9); 9.19 (1H, s, NH). ¹³C NMR spectrum, δ, ppm: 29.0 (5-CH₃); 36.2 (CH₂Ph); 46.9 (NCH₂); 59.2 7(CH₂O); 72.9 (C-3a); 84.7 (C-9b); 113.6 (C-6); 122.6 (C-8); 123.0 (C-9a); 126.1 (C-9); 126.7 (C-4 Ph); 126.8 (C-3,5 Ph); 129.2 (C-7); 130.0 (C-2,6 Ph); 132.2 (C-1 Ph); 135.6 10(C-5a); 168.1 (C-4); 181.8 (C-2). ¹⁵N NMR spectrum, δ, ppm (*J*, Hz): –237.9 (d, ¹*J* = 95.6, 1-NH); –250.3 (N-5); 12–254.0 (N-3). Mass spectrum, *m/z* (*I*_{rel.}, %): 789 [2M+Na]⁺ 13(10), 422 [M+K]⁺ (13), 406 [M+Na]⁺ (100), 403 [2M+Ca]²⁺ 14(15), 384 [M+H]⁺ (4). Mass spectrum, *m/z* (*I*_{rel.}, %): 765 15[2M–H][–] (47), 418 [M+³⁵Cl][–] (9), 382 [M–H][–] (100), 150 16(57). Found, %: C 62.83; H 5.51; N 10.84; S 8.53. 17C₂₀H₂₁N₃O₃S. Calculated, %: C 62.64; H 5.52; N 10.96; 18S 8.36.

19 **3a-Butyl-9b-hydroxy-3-(2-hydroxyethyl)-5-phenyl-2-thioxo-1,2,3,3a,5,9b-hexahydro-4H-imidazo[4,5-c]quinolin-4-one (6d)** was prepared from compound **2d**. Yield 9%. 22 White solid. Mp 220–226°C (PhH). IR spectrum, ν, cm^{–1}: 23 3283, 3169, 2958, 2932, 2872, 1654, 1606, 1596, 1464, 24 1430, 1398, 1356, 1304, 1257, 1207, 1127, 1070, 1051, 25 1006, 966, 945, 857, 754, 720, 699, 681, 649, 628, 586, 26 511. ¹H NMR spectrum, δ, ppm (*J*, Hz): 0.78 (3H, t, 27 *J* = 7.0, 4-CH₃ Bu); 1.12–1.31 (4H, m, 2,3-CH₂ Bu); 1.99–28 2.12 (2H, m, 1-CH₂ Bu); 3.59–3.67 (2H, m, CH₂O); 3.75–29 3.81 (1H, m) and 3.86–3.93 (1H, m, NCH₂); 4.60 (1H, t, 30 *J* = 6.2, OH); 6.14–6.17 (1H, m, H-6); 7.00 (1H, s, 9b-OH); 31 7.11–7.24 (4H, m, H-7,8, H-2,6 Ph); 7.50–7.54 (1H, m, 32 H-4 Ph); 7.57–7.62 (2H, m, H-3,5 Ph); 7.81–7.84 (1H, m, 33 H-9); 9.28 (1H, s, NH). ¹³C NMR spectrum, δ, ppm: 13.5 34(C-4 Bu); 22.5 (C-3 Bu); 24.3 (C-2 Bu); 31.7 (C-1 Bu); 35 46.6 (NCH₂); 59.0 (CH₂O); 72.5 (C-3a); 85.1 (C-9b); 115.5 36(C-6); 123.4 (C-8,9a); 126.8 (C-9); 128.3 (C-2,6 Ph); 128.7 37(C-4 Ph); 129.6 (C-7); 130.2 (C-3,5); 137.1 (C-5a); 137.4 38(C-1 Ph); 168.9 (C-4); 181.5 (C-2). ¹⁵N NMR spectrum, 39 δ, ppm (*J*, Hz): –231.0 (N-5); –237.7 (d, ¹*J* = 96.0, 1-NH); 40–254.6 (N-3). Mass spectrum, *m/z* (*I*_{rel.}, %): 845 [2M+Na]⁺ 41(7), 450 [M+K]⁺ (20), 434 [M+Na]⁺ (100), 431 [2M+Ca]²⁺ 42(12), 412 [M+H]⁺ (3). Mass spectrum, *m/z* (*I*_{rel.}, %): 821 43[2M–H][–] (21), 446 [M+³⁵Cl][–] (27), 410 [M–H][–] (29), 212 44(100). Found, %: C 64.14; H 6.28; N 9.98; S 7.85. 45 C₂₂H₂₅N₃O₃S. Calculated, %: C 64.21; H 6.12; N 10.21; 46 S 7.79.

47 **3a-Benzyl-9b-hydroxy-3-(2-hydroxyethyl)-5-phenyl-48 2-thioxo-1,2,3,3a,5,9b-hexahydro-4H-imidazo[4,5-c]-49 quinolin-4-one (6e)** was prepared from compound **2e**. 50 Yield 27%. Colorless solid. Mp 243–247°C (AcOEt). 51 IR spectrum, ν, cm^{–1}: 3387, 3192, 2933, 1652, 1598, 1491, 52 1475, 1432, 1397, 1358, 1303, 1239, 1199, 1134, 1067, 53 1038, 970, 854, 811, 755, 744, 717, 701, 608, 545, 524. 54 ¹H NMR spectrum, δ, ppm (*J*, Hz): 3.28 (1H, d, *J* = 16.0) 55 and 3.54 (1H, d, *J* = 16.0, CH₂Ph); 3.63–3.69 (1H, m) and 56 3.71–3.77 (1H, m, CH₂O); 3.97–4.06 (2H, m, NCH₂); 4.67 57(1H, t, *J* = 6.3, OH); 5.59–5.64 (1H, m, H-6); 6.70–6.85 58(2H, m, H Ph); 6.90–7.15 (7H, m, H-7,8, H Ph); 7.38 (1H, 59 s, 9b-OH); 7.38–7.53 (3H, m, H Ph); 7.75–7.80 (1H, m, 60 H-9); 9.39 (1H, s, NH). ¹³C NMR spectrum, δ, ppm: 36.3

(CH₂Ph); 46.9 (NCH₂); 59.2 (CH₂O); 73.3 (C-3a); 85.1 (C-9b); 61 115.1 (C-6); 123.0 (C-8); 123.1 (C-9a); 126.5 (C-9); 127.1 62 (C-4 5-Ph); 127.3 (C-3,5 5-Ph); 128.6 (C-3,5 CH₂Ph); 63 129.1 (C-4 CH₂Ph); 130.0 (C-7); 130.8 (C-2,6 CH₂Ph); 64 132.4 (C-1 CH₂Ph); 136.8 (C-5a); 137.1 (C-1 5-Ph); 167.9 65 (C-4); 181.8 (C-2). Mass spectrum, *m/z* (*I*_{rel.}, %): 913 66 [2M+Na]⁺ (8), 484 [M+K]⁺ (27), 468 [M+Na]⁺ (100), 465 67 [2M+Ca]²⁺ (7), 446 [M+H]⁺ (10). Mass spectrum, *m/z* (*I*_{rel.}, %): 68 889 [2M–H][–] (21), 480 [M+³⁵Cl][–] (43), 444 [M–H][–] (22), 69 212 (100). Found, %: C 67.36; H 5.28; N 9.24; S 7.27. 70 C₂₅H₂₃N₃O₃S. Calculated, %: C 67.40; H 5.20; N 9.43; S 7.20. 71

9b-Hydroxy-3-(2-hydroxyethyl)-3a,5-diphenyl-2-thioxo-72 1,2,3,3a,5,9b-hexahydro-4H-imidazo[4,5-c]quinolin-4-one 73 (6f) was prepared from compound **2f**. Yield 23%. Colorless 74 solid. Mp 228–235°C (AcOEt). IR spectrum, ν, cm^{–1}: 3230, 75 2957, 1685, 1661, 1605, 1594, 1491, 1464, 1431, 1390, 1341, 76 1307, 1260, 1195, 1140, 1077, 996, 945, 930, 863, 832, 77 759, 735, 704, 691, 630, 606, 589, 574, 532, 513. ¹H NMR 78 spectrum, δ, ppm (*J*, Hz): 3.27–3.40 (1H, m, NCH₂); 3.60–79 3.74 (2H, m, NCH₂, OCH₂); 3.87–3.99 (2H, m, OCH₂); 80 4.55 (1H, t, *J* = 5.7, OH); 6.29–6.33 (1H, m, H-6); 7.00 81 (1H, s, 9b-OH); 7.07–7.13 (1H, m, H-8); 7.20–7.26 (1H, m, 82 H-7); 7.27–7.50 (7H, m, H-2,6 5-Ph, H-2,3,4,5,6 3a-Ph); 83 7.53–7.58 (1H, m, H-4 5-Ph); 7.61–7.69 (2H, m, H-9, H-3,5 84 5-Ph); 9.55 (1H, s, NH). ¹³C NMR spectrum, δ, ppm: 48.7 85 (NCH₂); 58.4 (CH₂O); 79.0 (C-3a); 86.5 (C-9b); 116.2 (C-6); 86 122.5 (C-9a); 123.5 (C-8); 128.0 (C-9); 128.2 (C-2,6 3a-Ph); 87 128.8 (C-3,5 3a-Ph, C-2,6 5-Ph); 129.9 (C-7); 130.3 (C-3,5 88 5-Ph); 131.8 (C-1 3a-Ph); 137.4 (C-5a); 137.6 (C-1 5-Ph); 89 168.0 (C-4); 184.5 (C-2). Mass spectrum, *m/z* (*I*_{rel.}, %): 885 90 [2M+Na]⁺ (4), 470 [M+K]⁺ (15), 454 [M+Na]⁺ (100), 451 91 [2M+Ca]²⁺ (9), 432 [M+H]⁺ (5). Mass spectrum, *m/z* (*I*_{rel.}, %): 92 861 [2M–H][–] (4), 466 [M+³⁵Cl][–] (20), 430 [M–H][–] (59), 93 212 (100). Found, %: C 66.64; H 4.93; N 9.53; S 7.68. 94 C₂₄H₂₁N₃O₃S. Calculated, %: C 66.80; H 4.91; N 9.74; S 7.43. 95

3-(2-Hydroxyethyl)-5-methyl-2-thioxo-1,2,3,5-tetrahydro- 96 4H-imidazo[4,5-c]quinolin-4-one (7b) was prepared from 97 compound **2b**. Yield 8%. Yellowish solid. Mp 295–310°C 98 (cyclohexane–AcOEt). IR spectrum, ν, cm^{–1}: 3347, 3074, 99 2925, 2842, 2730, 1670, 1635, 1587, 1524, 1483, 1427, 100 1393, 1358, 1327, 1261, 1211, 1164, 1115, 1074, 1063, 101 1043, 1009, 969, 884, 863, 768, 754, 733, 677, 626, 585, 102 520. ¹H NMR spectrum, δ, ppm (*J*, Hz): 3.66 (3H, s, CH₃); 103 3.71 (2H, t, *J* = 6.6, CH₂O); 4.56 (2H, t, *J* = 6.6, NCH₂); 104 4.84 (1H, br. s, OH); 7.31–7.36 (1H, m, H-8); 7.52–7.62 105 (1H, m, H-6,7); 8.05–8.09 (1H, m, H-9); 13.75 (1H, s, 106 NH). ¹³C NMR spectrum, δ, ppm: 28.9 (CH₃); 46.3 107 (NCH₂); 58.4 (CH₂O); 110.0 (C-3a); 115.7 (C-6); 117.7 108 (C-9a); 122.0 (C-8); 122.5 (C-9); 129.4 (C-7); 131.5 109 (C-9b); 136.8 (C-5a); 153.2 (C-2); 167.1 (C-4). ¹⁵N NMR 110 spectrum, δ, ppm (*J*, Hz): –220.3 (N-3); –223.1 (d, ¹*J* = 97.5, 111 1-NH); –240.0 (N-5). Mass spectrum, *m/z* (*I*_{rel.}, %): 573 112 [2M+Na]⁺ (73), 432.5 [3M+Ca]²⁺ (11), 314 [M+K]⁺ (9), 113 298 [M+Na]⁺ (100), 276 [M+H]⁺ (21). Mass spectrum, 114 *m/z* (*I*_{rel.}, %): 571 [2M–2H+Na][–] (12), 274 [M–H][–] (100). 115 Found, %: C 56.48; H 4.66; N 15.01; S 11.84. 116 C₁₃H₁₃N₃O₂S. Calculated, %: C 56.71; H 4.76; N 15.26; 117 S 11.65. 118

3-(2-Hydroxyethyl)-5-phenyl-2-thioxo-1,2,3,5-tetrahydro- 119 4H-imidazo[4,5-c]quinolin-4-one (7e) was prepared from 120

1 compound **2e**. Yield 8%. Colorless solid. Mp 275–290°C
 2 (AcOEt). IR spectrum, ν , cm^{-1} : 3426, 3056, 2924, 2740,
 3 1668, 1634, 1591, 1569, 1521, 1480, 1463, 1434, 1394,
 4 1341, 1324, 1267, 1238, 1210, 1164, 1121, 1072, 1029,
 5 989, 860, 786, 753, 732, 699, 683, 608, 563, 515. ^1H NMR
 6 spectrum, δ , ppm (J , Hz): 3.71 (2H, td, $J = 6.7$, $J = 5.7$,
 7 CH_2O); 4.56 (2H, t, $J = 6.7$, NCH_2); 4.88 (1H, t, $J = 5.7$, OH);
 8 6.56–6.61 (1H, m, H-6); 7.31–7.45 (4H, m, H-7,8, H-2,6 Ph);
 9 7.55–7.68 (3H, m, H-3,4,5 Ph); 8.16–8.20 (1H, m, H-9);
 10 13.95 (1H, s, NH). ^{13}C NMR spectrum, δ , ppm: 46.4 (NCH_2);
 11 58.5 (CH_2O); 110.1 (C-3a); 116.5 (C-6); 117.9 (C-9a);
 12 122.1 (C-9); 122.8 (C-8); 129.0 (C-4 Ph); 129.3 (C-7); 129.4
 13 (C-2,6 Ph); 130.1 (C-3,5 Ph); 132.4 (C-9b); 137.2 (C-5a);
 14 138.3 (C-1 Ph); 152.5 (C-2); 167.4 (C-4). ^{15}N NMR spectrum,
 15 δ , ppm (J , Hz): –219.1 (N-5); –220.3 (N-3); –223.9 (d,
 16 $^1J = 96.6$, 1-NH). Mass spectrum, m/z (I_{rel} , %): 697
 17 $[2\text{M}+\text{Na}]^+$ (14), 376 $[\text{M}+\text{K}]^+$ (11), 360 $[\text{M}+\text{Na}]^+$ (100), 338
 18 $[\text{M}+\text{H}]^+$ (16). Mass spectrum, m/z (I_{rel} , %): 336 $[\text{M}-\text{H}]^-$ (100).
 19 Found, %: C 63.95; H 4.50; N 11.98; S 9.27. $\text{C}_{18}\text{H}_{15}\text{N}_3\text{O}_2\text{S}$.
 20 Calculated, %: C 64.08; H 4.48; N 12.45; S 9.50.
 21 **1'-Methyl-7a-phenyl-5-thioxo-2,3,5,6-tetrahydro-7aH-**
 22 **spiro[imidazo[5,1-b]oxazole-7,3'-indolin]-2'-one (8c)** was
 23 prepared from compound **2c**. Yield 49%. White solid. Mp
 24 221–224°C (hexane–AcOEt). IR spectrum, ν , cm^{-1} : 3289,
 25 3058, 3033, 2968, 2901, 1710, 1612, 1472, 1356, 1293,
 26 1260, 1233, 1193, 1154, 1127, 1093, 1072, 1052, 1024,
 27 1005, 991, 948, 915, 857, 784, 753, 703, 687, 653, 623,
 28 588, 532. ^1H NMR spectrum, δ , ppm: 2.67 (3H, s, CH_3);
 29 3.22–3.30 (1H, m, 2- CH_2); 3.40–3.46 and 3.86–3.93 (2H,
 30 m, 3- CH_2); 4.51–4.56 (2H, m, 2- CH_2); 6.94–7.01 (3H, m,
 31 H-7', H Ph); 7.14–7.18 (1H, m, H-5'); 7.20–7.32 (3H, m,
 32 H Ph); 7.43–7.48 (1H, m, H-6'); 7.53–7.56 (1H, m, H-4');
 33 9.98 (1H, s, NH). ^{13}C NMR spectrum, δ , ppm: 25.8 (CH_3);
 34 47.9 (C-3); 62.8 (C-2); 71.7 (C-7); 102.9 (C-7a); 108.6
 35 (C-7'); 121.6 (C-3a'); 122.4 (C-5'); 126.0 (C-2,6); 127.7
 36 (C-3,5); 127.9 (C-4'); 129.0 (C-4 Ph); 130.8 (C-6'); 134.2
 37 (C-1 Ph); 144.2 (C-7'); 172.0 (C-2'); 191.9 (C-5). ^{15}N NMR
 38 spectrum, δ , ppm (J , Hz): 244.7 (N-4); –246.9 (d, $^1J = 96.6$,
 39 6-NH); –252.0 (N-1'). Mass spectrum, m/z (I_{rel} , %): 352
 40 $[\text{M}+\text{H}]^+$ (100). Mass spectrum, m/z (I_{rel} , %): 350 $[\text{M}-\text{H}]^-$ (100).
 41 Found, %: C 65.12; H 5.01; N 11.72; S 9.28. $\text{C}_{19}\text{H}_{17}\text{N}_3\text{O}_2\text{S}$.
 42 Calculated, %: C 64.94; H 4.88; N 11.96; S 9.12.
 43 **Conversion of compounds 6a,e,f to compounds 5a,f**
 44 **and 9e**. P_2O_5 (43 mg, 0.30 mmol) was added portionwise
 45 to a stirred solution of compound **6a,e,f** (0.20 mmol) in
 46 CHCl_3 (4.0 ml) at room temperature. After 45 min, the
 47 yellow solution was filtered through a short column of
 48 silica gel. The filtrate was evaporated to dryness, and the
 49 residue was crystallized. From compounds **6a,f**, com-
 50 pounds **5a,f**, identical in all respect to those prepared from
 51 compounds **2a,f**, were obtained in 59 and 73% yields,
 52 respectively. From compound **6e**, colorless compound **9e**
 53 was obtained in 39% yield besides compound **7e** (5%).
 54 **2-(Benzylsulfanyl)-3-(2-hydroxyethyl)-5-phenyl-3,5-**
 55 **dihydro-4H-imidazo[4,5-c]quinolin-4-one (9e)**. Colorless
 56 solid. Mp 182–186°C (hexane–benzene). IR spectrum, ν , cm^{-1} :
 57 3317, 3061, 3031, 2962, 1670, 1575, 1492, 1456, 1430,
 58 1359, 1309, 1247, 1223, 1163, 1128, 1056, 1036, 947, 852,
 59 757, 702, 681, 666, 607, 563, 546. ^1H NMR spectrum,
 60 δ , ppm (J , Hz): 3.64–3.69 (2H, m, CH_2O); 4.32–4.36 (2H,

m, NCH_2); 4.64 (2H, s, SCH_2); 4.96 (1H, t, $J = 6.9$, OH); 61
 6.55–6.59 (1H, m, H-6); 7.24–7.37 (7H, m, H-7,8,62
 H-2,3,4,5,6 5-Ph); 7.47–7.51 (2H, m, H-2,6 CH_2Ph); 7.58–63
 7.62 (1H, m, H-4 CH_2Ph); 7.62–7.66 (2H, m, H-3,5 64
 CH_2Ph); 8.23–8.27 (1H, m, H-9). ^{13}C NMR spectrum, 65
 δ , ppm: 36.5 (SCH_2); 48.0 (NCH_2); 60.1 (CH_2O); 116.0 (C-9a); 66
 116.3 (C-6); 121.1 (C-3a); 121.8 (C-9); 122.6 (C-8); 127.5 67
 116.3 (C-6); 121.1 (C-3a); 121.8 (C-9); 122.6 (C-8); 127.5 67
 (C-4 5-Ph); 128.2 (C-7); 128.5 (C-2,6 5-Ph); 128.8 (C-4 68
 CH_2Ph); 129.0 (C-2,6 CH_2Ph); 129.6 (C-3,5 5-Ph); 130.0 69
 (C-3,5 CH_2Ph); 137.4 (C-1 CH_2Ph); 137.6 (C-1 5-Ph); 70
 138.4 (C-5a); 143.9 (C-9b); 152.5 (C-2); 154.1 (C-4). 71
 ^{15}N NMR spectrum, δ , ppm: –137.2 (N-1); –217.6 (N-3); 72
 –220.9 (N-5). Mass spectrum, m/z (I_{rel} , %): 877 $[2\text{M}+\text{Na}]^+$ 73
 (5), 466 $[\text{M}+\text{K}]^+$ (8), 450 $[\text{M}+\text{Na}]^+$ (63), 428 $[\text{M}+\text{H}]^+$ 74
 (100). Mass spectrum, m/z (I_{rel} , %): 426 $[\text{M}-\text{H}]^-$ (100). 75
 Found, %: C 70.46; H 5.09; N 9.56; S 7.47. $\text{C}_{25}\text{H}_{21}\text{N}_3\text{O}_2\text{S}$. 76
 Calculated, %: C 70.24; H 4.95; N 9.83; S 7.50. 77

Supplementary information file containing ^1H , ^{13}C , and 78
 $^1\text{H}-^{15}\text{N}$ HMBC NMR spectra of the synthesized compounds 79
 is available at the journal website <http://hgs.osi.lv>. 80

A. K. and M. R. thank for financial support from the 81
 internal grant of TBU in Zlín (No. IGA/FT/2019/010), 82
 funded from the resources of specific university research. 83
 The authors thank Mrs. H. Geržová (Faculty of Technology, 84
 Tomas Bata University in Zlín) for technical help. 85

References 86

1. (a) Kafka, S.; Klásek, A.; Polis, J.; Košmrlj, J. *Heterocycles* 87
2002, 57, 1659. (b) Klásek, A.; Kořistek, K.; Lyčka, A.; 88
 Holčapek, M. *Tetrahedron* **2003**, 59, 1283. (c) Klásek, A.; 89
 Kořistek, K.; Lyčka, A.; Holčapek, M. *Tetrahedron* **2003**, 59, 90
 5279. (d) Klásek, A.; Lyčka, A.; Holčapek, M. *Tetrahedron* 91
2007, 63, 7059. (e) Klásek, A.; Lyčka, A.; Holčapek, M.; 92
 Hoza, I. *Helv. Chim. Acta* **2008**, 91, 354. (f) Prucková, Z.; 93
 Klásek, A.; Lyčka, A.; Mikšík, I.; Růžička, A. *Tetrahedron* 94
2009, 65, 9103. (g) Mrkvička, V.; Lyčka, A.; Rudolf, O.; 95
 Klásek, A. *Tetrahedron* **2010**, 66, 8441. (h) Klásek, A.; 96
 Křemen, F.; Křemenová, H.; Lyčka, A.; Rouchal, M. 97
Tetrahedron **2017**, 73, 1583. (i) Klásek, A.; Lyčka, A.; 98
 Holčapek, M.; Kovář, M.; Hoza, I. *J. Heterocycl. Chem.* **2006**, 99
 43, 1251. 100
2. Shin, Y. S.; Song, S. J.; Kang, S. U.; Hwang, H. S.; Choi, J. W.; 101
 Lee, B. H.; Jung, Y.-S.; Kim, C.-H. *Neurosciences* **2013**, 232, 1. 102
3. Cifuentes-Pagano, M. E.; Meijles, D. N.; Pagano, P. J. *Curr.* 103
Pharm. Design **2015**, 21, 6023. 104
4. Mittal, R.; Debs, L. H.; Nguyen, D.; Patel, A. P.; Grati, M.; 105
 Mittal, J.; Yan, D.; Eshraghi, A. A.; Liu, X. Z. *J. Cell. Physiol.* 106
2017, 232, 2710. 107
5. Marckwald, W. *Ber. Dtsh. Chem. Ges.* **1892**, 25, 2354. 108
6. Borduas, N.; Place, B.; Wentworth, G. R. F.; Abbatt, P. D.; 109
 Murphy, J. G. *Atmos. Chem. Phys.* **2016**, 16, 703. 110
7. Ermans, A.-M.; Bourdoux, P. In *Environmental* 111
Goitrogenesis; Gaitan, E., Ed.; CRC Press: Boca Raton, 1989, 112
 p. 15. 113
8. Chiang, Y.; Kresge, A. J. *Can. J. Chem.* **2000**, 78, 1627. 114
9. Berger, S.; Braun, S. *200 and More NMR Experiments: A* 115
Practical Course; Wiley-VCH: Weinheim, 2004, 3rd ed. 116
10. Claridge, T. D. W. *High-Resolution NMR Techniques in* 117
Organic Chemistry; Elsevier: Amsterdam, 2016, 3rd ed. 118
11. Marek, R.; Lyčka, A.; Kolehmainen, E.; Sievanen, E.; 119
 Toušek, J. *Curr. Org. Chem.* **2007**, 11, 1154. 120